Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLMNFX)

Drug Name

Omaveloxolone Drug Info

Synonyms

RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563

Indication

Disease Entry	ICD 11	Status	REF
Friedreich's ataxia	8A03.10	Approved	[1]
Melanoma	2C30	Phase 1/2	[2]
Psychiatric disorder	6E8Z	Clinical trial	[3]

Cross-matching ID

PubChem CID: 71811910
CAS Number: CAS 1474034-05-3
TTD Drug ID: DMLMNFX

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nuclear factor erythroid 2-related factor 2 (Nrf2)	TTA6ZN2	NF2L2_HUMAN	Activator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Nuclear factor erythroid 2-related factor 2 (Nrf2)	DTT	NFE2L2	8.964	8.362	9.046	8.808

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Friedreich's ataxia

ICD Disease Classification

8A03.10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Nuclear factor erythroid 2-related factor 2 (Nrf2)	DTT	NFE2L2	4.75E-12	-0.28	-0.58

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216718.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin. Arch Dermatol Res. 2014 Jul;306(5):447-54.